Advertisements

Gino-Canesten

Quick links to important sections

Gino-Canesten

Selected form

Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Gino-Canesten

Property Description
Active ingredient Clotrimazol (Clotrimazole)
Forms Vaginal tablet (pessary), Vaginal cream
Pharmacological class Azole Antifungal / Antimycotic
General purpose Resolving fungal and yeast infections
Origin Synthetic Imidazole Derivative

Definition and Classification

Gino-Canesten is fundamentally an antimycotic drug whose medicinal identity is the single active ingredient, Clotrimazol (Clotrimazole). This compound is classified within the Azole antifungal class, specifically as a synthetic imidazole derivative, reflecting its precise chemical structure. As a monopreparation, it is designed solely around the efficacy of Clotrimazol. This classification is clinically recognized for its effectiveness against a wide variety of fungal and yeast organisms. The identity of Gino-Canesten is centered on delivering this specific antifungal action, primarily targeting conditions such as vulvovaginal candidiasis in adult patient groups.

General Therapeutic Purpose

The primary general purpose of Clotrimazol is to mitigate the proliferation of fungal organisms by targeting their fundamental viability. The drug acts as an inhibitor of fungal cell growth by interfering with the synthesis of ergosterol, a crucial structural component of the fungal cell membrane. By compromising this essential barrier, the medication halts the growth and replication of the organism. This mechanism of action directly results in the therapeutic benefit of resolving the underlying fungal infections, enabling the body to recover from the associated irritation and discomfort.

Available Dosage Forms

Clotrimazol is formulated into specific dosage forms intended for topical or mucosal administration to ensure localized efficacy. The primary preparations for vaginal use include the solid vaginal tablet (pessary) and the smooth vaginal cream, which utilizes a standard cream base. This dual-form availability, typical of the Gino-Canesten product line, provides patients with flexibility in delivery method. Other dermatological preparations, such as solution and lotion forms, may also be available for external surface application. The localized application ensures the active ingredient is highly concentrated directly at the required site of action.

Regulatory References

  1. Clotrimazole Vaginal: MedlinePlus Drug Information
Advertisements

What side effects are possible with Gino-Canesten?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety considerations for Gino-Canesten (clotrimazole), based strictly on governmental regulatory documents.

Adverse Reaction Scope

Adverse reactions are primarily localized to the application site. Systemic adverse effects are rare due to minimal absorption of the active substance.

Category Examples (Reported Reactions)
Application Site Effects Burning sensation, stinging, pruritus (itching), irritation, erythema (redness), discomfort, peeling/exfoliation.
Immune System Disorders Systemic hypersensitivity reactions, including angioedema (swelling), rash, urticaria (hives), and severe allergic reactions (anaphylactic reaction).

Most serious systemic reactions are based on spontaneous post-marketing reports and are often classified as Frequency Not Known (cannot be estimated from the available data).

Serious Adverse Reactions

Although rare, systemic allergic reactions are documented serious risks. These may include anaphylactic reactions, which can involve symptoms such as difficulty breathing (dyspnea) or a sudden drop in blood pressure (hypotension). Treatment must be discontinued immediately if any signs of hypersensitivity or severe local irritation occur.

Safety-Related Restrictions and Limitations

Latex Barrier Contraceptives: The excipients in some formulations (creams/pessaries) can damage latex-based products, such as condoms and diaphragms. This damage reduces the effectiveness of the barrier method. Patients are advised to use alternative contraceptive methods during treatment and for a period following treatment (typically five days).

Use in Specific Populations: Use during pregnancy (especially the first trimester) and breastfeeding should be under the direction of a doctor, though minimal systemic absorption suggests a low overall risk to the foetus or nursing infant.

Summary of the Safety Profile

The official safety information indicates that the drug's risk profile is characterized by a high expectation of mild, transient local application site reactions. The primary safety concern is the need to monitor for rare but severe systemic allergic reactions and the specific regulatory limitation regarding the use of latex barrier contraceptives.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation emphasizes that acute intoxication following the recommended vaginal or dermal application of Clotrimazol (Gino-Canesten) is unlikely. This is due to the minimal systemic absorption of the active ingredient into the body. The primary overdose concern addressed in regulatory labeling is that of inadvertent oral ingestion of the preparation.

Overdose Context Official Statement
Documented Symptoms Accidental oral ingestion may lead to documented clinical manifestations that include nausea, vomiting, and dizziness.
Systemic Risk Overdosage from the topical or vaginal application route is not expected to lead to a life-threatening situation.

Required Emergency Actions

Immediate medical attention must be sought in the event of accidental ingestion. Regulators mandate that individuals seek professional assistance or contact a Poison Control Center immediately. In circumstances where the affected individual has collapsed or is not breathing, emergency services should be contacted.

Official Management and Antidote Status:

  • The official labeling states that no specific antidote is known for Clotrimazol overdose.
  • Supportive and symptomatic treatment is the generally described approach.
  • Measures such as gastric lavage should only be considered if clinical symptoms of overdose become apparent and only under conditions where the airway can be adequately protected by medical personnel.
Advertisements

Therapeutic Uses of Gino-Canesten

The primary therapeutic role of Gino-Canesten (Clotrimazol) is to provide localized symptomatic relief and treatment for infections caused by Candida fungi. The medication is considered relevant in clinical settings marked by the heightened patient distress associated with these common infections. Within this context, Clotrimazole is used for the treatment of vaginal yeast infections.

Treatment of Acute Fungal Vaginal Infections

Gino-Canesten is commonly used for the management of vulvovaginal candidiasis, generally known as a vaginal yeast infection or thrush. This is applicable within clinical settings that involve acute or disruptive symptom patterns. Its therapeutic application supports the management of fungal overgrowth, which helps ease the overall symptom burden and contributes to easing the overall symptom load during symptomatic periods.

Relief of Intense Local Symptomatic Distress

The therapeutic relevance is in addressing symptom clusters that may become intense or disruptive, such as pronounced manifestations of vaginal itching (pruritus), a burning sensation, and vulvar soreness. The medication may be applied in scenarios where additional management of discomfort is required, offering symptomatic relief that helps patients cope more steadily with difficult episodes.


Quick Fact: Relief for Local Symptom Distress

The treatment is commonly used to help with symptoms that interfere with daily functioning, providing supportive relief when symptoms disrupt routine activities and may assist with maintaining a sense of stability.

Regulatory References

  1. MedlinePlus Drug Information overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Gino-Canesten

Official regulatory documents define strict eligibility criteria for the use of Clotrimazole preparations. Eligibility is determined by age, medical status, and the presence of complicating symptoms, ensuring the medication is appropriate for the user.

Contraindications and Absolute Exclusions

Use of this medicine is absolutely contraindicated in individuals with a known history of hypersensitivity or allergy to Clotrimazole or any of the product's inactive ingredients.

Furthermore, patients with certain systemic symptoms—such as fever, chills, lower abdominal or back pain, unusual vaginal bleeding, or foul-smelling discharge—are excluded from self-treatment eligibility, as these symptoms may indicate a condition more serious than a simple yeast infection.

Age and Condition-Based Restrictions

Population Group Regulatory Status
Children Under 12 Not approved for self-treatment; requires professional consultation.
Pregnant/Breastfeeding Consultation with a healthcare professional is mandatory before use.
Diabetics or Immunocompromised Eligibility requires professional consultation due to risk of recurrent or serious underlying infection.
Recurrent Infections Not recommended for self-treatment if experiencing frequent infections (e.g., three in six months).

Eligibility is generally permitted for adults and adolescents 12 years and over for previously diagnosed, infrequent vaginal yeast infections.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Clotrimazol vaginal formulations documents two distinct interaction categories. The low level of systemic absorption of the active component dictates a narrow scope for systemic drug-drug interactions, which are classified as pharmacokinetic effects on specific, sensitive co-administered medications.

Documented Drug-Drug Interaction

Classification Interacting Substance Official Outcome Statement
Pharmacokinetic Tacrolimus (Oral) Co-administration may result in an increase in the plasma concentration of the immunosuppressant.
Pharmacokinetic Sirolimus (Oral) Co-administration may result in an increase in the plasma concentration of the immunosuppressant.

This effect on oral Tacrolimus and Sirolimus is recognized as a clinically significant pharmacokinetic interaction because the concentration of the immunosuppressant may be altered.

Physical and Timing-Based Restrictions

A separate physicochemical interaction is documented involving barrier methods: the product contains ingredients that can cause damage to latex-based contraceptives, such as condoms and diaphragms. This effect carries an official risk of reduced effectiveness for the contraceptive device.

Consequently, a mandatory timing-based restriction is defined in regulatory documents: individuals must use alternative or non-latex barrier precautions for a minimum period of five days following the use of this product.

No interactions with food, alcohol, herbal products, or supplements are formally specified in official government documentation for the vaginal formulation.

Advertisements

Mechanism of Action

Disrupting the Fungal Ergosterol Pathway

The action of Clotrimazol centers on the targeted inhibition of a specific fungal enzyme: C14alpha-demethylase, a member of the cytochrome P450 family. This enzyme is essential for the fungal organism to complete the Ergosterol biosynthesis pathway. By blocking this critical step, the drug prevents the production of Ergosterol, the vital structural component of the fungal cell membrane, initiating the mechanism leading to fungal cellular damage.


Causing Fungal Cell Membrane Failure

Inhibition of the Ergosterol pathway causes abnormal C14 methyl sterols to build up and incorporate into the fungal membrane. This process compromises the membrane's structural integrity and increases its permeability. Consequently, essential cellular contents, such as potassium ions and amino acids, leak out, which results in fungal growth arrest (fungistasis) and leads to cellular lysis (fungicide), thereby removing the organism that serves as the local biological trigger.

Advertisements

Dosage and Administration Information

The use of Gino-Canesten, which contains the active ingredient clotrimazol, is strictly governed by administration patterns established in official documents. The medicine is delivered via the intravaginal route for both the cream and the vaginal tablet (pessary) forms, with external topical application of the cream also approved for vulvar use. The standard use protocols define specific dose strengths and corresponding short-term durations.

Dosage Form and Strength Frequency Pattern Standard Duration
500 mg Vaginal Tablet Single application 1 day
200 mg Vaginal Tablet Once daily 3 days
100 mg Vaginal Tablet Once daily 6 or 7 days
1% Vaginal Cream Once daily (one applicatorful) 7 days

The single daily application is generally directed to occur at bedtime. This specific timing is detailed in instructions to allow the medicine to remain concentrated at the application site. These standard regimens are officially applied to adults and adolescents 12 years of age and over. Administration for individuals under the age of 12 is generally not detailed within standard official patient instructions.

A key procedural constraint in the official use of the medicine involves administration context. Guidelines specify that patients should avoid the concurrent use of spermicides, douches, or tampons during the course of treatment, as these products may interfere with the physical properties of the medicine or its application pattern. Furthermore, administration guidelines advise abstinence from vaginal intercourse throughout the entire prescribed course of treatment. If a scheduled daily dose is missed, regulatory principles suggest administering the dose as soon as the lapse is noted, and then returning to the regular schedule thereafter.

Advertisements

Recent Clinical Evidence

Gino-Canesten: Recent Clinical Evidence

Gino-Canesten contains clotrimazole, an imidazole antifungal agent used for treating vulvovaginal candidiasis (VVC), commonly known as a vaginal yeast infection. Clinical evidence for clotrimazole is extensive, spanning decades of use in gynecological health.

Efficacy in Uncomplicated VVC

Systematic reviews of randomized controlled studies consistently assess the efficacy and safety of topical clotrimazole. Research on women with uncomplicated VVC often focuses on mycological (fungal clearance) and clinical cure rates.

  • Single-dose efficacy: Studies report that a single intravaginal dose of clotrimazole (e.g., 500 mg vaginal tablets) provides high cure rates comparable to, or equipotent with, multi-day regimens of lower dose strengths or some oral antifungal agents.
  • Treatment duration: The evidence supports that prolonged treatment regimens may be suitable for more complicated cases of VVC, such as severe, recurrent infections, and in symptomatic pregnant women.

Comparative Findings and Safety Profile

Clotrimazole is often studied alongside other antifungal treatments. For instance, some research has compared high-dose intravaginal clotrimazole to oral fluconazole for severe VVC, reporting similar clinical outcomes in the study cohorts. The continued widespread use of the drug is supported by its well-established clinical data and a low incidence of clotrimazole resistance in Candida albicans, the most common causative organism for VVC.

The most commonly reported side effects in studies are local reactions, such as mild vulvar or vaginal burning or irritation, with minimal systemic absorption reported following intravaginal use.

Key Studies & References

  1. One-day treatment of vulvovaginal candidiasis with a 500-mg clotrimazole vaginal tablet compared with a three-day regimen of two 100-mg vaginal tablets daily (Randomized Controlled Trial)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Gino-Canesten (FAQ)

Q: Is it normal to feel a temporary mild burning sensation after using Gino-Canesten?

A: Official information indicates that local reactions, such as a burning sensation, stinging, or irritation at the application site, are common side effects. These effects are typically described as mild and transient, meaning they are brief and temporary. Patients are generally advised in regulatory guidance to monitor for severe or persistent irritation.


Q: Can Gino-Canesten be used during the menstrual period?

A: Some official guidance states that treatment interruption is generally not required during the menstrual period. However, regulatory guidelines specify that patients should avoid using tampons or douches throughout the prescribed course of treatment, as these may interfere with the medicine.


Q: What happens if I stop using Gino-Canesten too soon?

A: Regulatory guidance describes the importance of using the medication for the full prescribed time. Studies and official information indicate that prematurely stopping the medication may be associated with the return of symptoms or incomplete clearance of the infection.


Q: What is the general recommended treatment length for a yeast infection using Gino-Canesten?

A: Treatment length varies based on the specific product formulation. Official dosage patterns include single-day, three-day, or six- to seven-day regimens. Clinical evidence reports that single-dose or three-day treatments show comparable clearance rates for uncomplicated cases of the infection.


Q: Can Gino-Canesten be used if someone is taking oral contraceptives?

A: Regulatory reports on the active ingredient (clotrimazole) suggest a minimal potential for interaction with oral contraceptives due to the low systemic absorption from vaginal products. However, regulatory documents indicate that the systemic concentration of hormonal contraceptives may be altered, which is a pharmacokinetic consideration.


Q: What are the most serious side effects mentioned in regulatory documents for Gino-Canesten?

A: The most serious documented effects are systemic hypersensitivity and allergic reactions. These are rare but may include anaphylactic reaction, which is a severe allergic response, as well as swelling (angioedema), difficulty breathing, and a sudden drop in blood pressure.


Q: What are the common ingredients found in the Gino-Canesten formulations?

A: The active ingredient is clotrimazole. Official product descriptions for the cream formulation often list common inactive ingredients (excipients) such as cetostearyl alcohol, benzyl alcohol, and purified water. These inactive ingredients are necessary to formulate the cream base.


Q: Is there a link between using Gino-Canesten and getting a skin rash?

A: Rash is a documented possible side effect in regulatory documents. It can appear either as a localized skin reaction, potentially due to sensitivity to the ingredients, or as a sign of a more general systemic hypersensitivity reaction.


Q: Can people with certain chronic conditions use Gino-Canesten?

A: Official eligibility criteria state that professional consultation is mandatory for individuals with certain chronic conditions, such as diabetes or those who are immunocompromised. This requirement is due to the potential risk of the infection being recurrent or related to a more serious underlying condition.


Q: Is Gino-Canesten available over the counter?

A: In many regions, the active ingredient in Gino-Canesten (clotrimazole) is available for purchase over the counter (OTC) for treating vaginal yeast infections. However, the exact availability and product registration status may vary based on the local health authority in different countries.


Q: Can Gino-Canesten be used by women who are not pregnant?

A: Official guidance indicates that the product is intended for the treatment of vulvovaginal candidiasis. Use is generally permitted for adult and adolescent women who are not pregnant and who meet the general eligibility criteria for the medicine.


Q: Is Gino-Canesten an antibiotic?

A: No, Gino-Canesten is classified as an antimycotic, or antifungal drug. The medicine’s action specifically targets fungal cells, and its mechanism is chemically and pharmacologically distinct from how antibiotics work to treat bacterial infections.


Q: How quickly should I start to notice an effect after using Gino-Canesten?

A: Regulatory-cited clinical data suggests that relief from symptoms may begin a few days after the initial application. Completing the entire treatment course is described as necessary to achieve the full therapeutic effect and clearance of the fungal organism.


Q: Can men use Gino-Canesten for related issues?

A: The active ingredient, clotrimazole, is used in topical cream formulations to treat related fungal conditions in men. Official guidance states that men are advised to seek medical advice before use, particularly if they are uncertain about the cause of their symptoms.


Q: What are some common misconceptions about how Gino-Canesten should be applied?

A: Official product instructions address common misunderstandings by advising that internal forms should be used at bedtime to help keep the medicine concentrated at the application site. Regulatory instructions define the need to complete the full course of treatment and to avoid using certain products like douches or tampons during therapy.


Q: Is it possible for the symptoms to temporarily worsen after starting Gino-Canesten?

A: Regulatory information lists application site effects such as burning, stinging, or irritation as common side effects. While the product is intended to relieve symptoms, these transient local reactions may be perceived by the patient as a temporary worsening of existing symptoms.


Q: Does Gino-Canesten cause headaches or nausea?

A: Nausea is sometimes listed as a possible side effect of the active ingredient, clotrimazole, particularly with oral use. Headache may also be associated with some of the rare, more severe systemic reactions documented in regulatory safety profiles.


Q: Is the effect of Gino-Canesten instantaneous?

A: The drug's action involves interfering with the synthesis of the fungal cell membrane. This process begins immediately upon application, but it requires a period of time to fully disrupt the cell and lead to fungal growth arrest. Therefore, the full therapeutic effect is not instantaneous.


Q: Are there any known issues with using Gino-Canesten with other topical treatments?

A: Official guidance specifically restricts the simultaneous use of spermicides, douches, or tampons. Furthermore, regulatory information advises that the development of irritation or sensitivity may require the cessation of other local treatments.


Q: Are there any known long-term effects associated with repeated use of Gino-Canesten?

A: Summary regulatory documents do not typically detail specific long-term effects on humans from repeated vaginal use. However, preclinical data on repeated use of the active ingredient has not suggested special hazards.


Q: Does Gino-Canesten contain latex or other common allergens?

A: The official product information does not list latex as an ingredient. However, excipients (inactive ingredients) like cetostearyl alcohol and benzyl alcohol are listed and are known to potentially cause local skin reactions or allergic contact dermatitis in sensitive individuals.


Q: What are the main differences between the single-dose and multi-day treatments of Gino-Canesten?

A: Regulatory-cited clinical trials indicate that the high-dose, single-day treatment is comparable in efficacy and safety to multi-day regimens of lower strength. The choice between these two options is often guided by factors such as patient preference and the severity or recurrence status of the infection.

Advertisements

How should Gino-Canesten be stored and disposed of?

Storage and Disposal of Clotrimazole Vaginal Products

Official regulatory labeling dictates specific conditions for storing and disposing of clotrimazole vaginal cream and tablets (pessaries) to ensure product stability and environmental safety.

Required Storage Conditions

Condition Regulatory Requirement
Temperature Store at or below 25 C (77 F); the product must not be frozen.
Container Keep the medicine in the original container and ensure it is tightly closed.
Protection Protect from moisture and, for the vaginal tablet form, protect from light.
Child Safety The medicine must be kept out of the sight and reach of children.

Official Disposal Rules

Unused or expired clotrimazole products must not be disposed of via wastewater or household waste, including flushing applicators down the toilet. For proper environmental protection, the unused product should be returned to a pharmacist or a designated drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gino-Canesten found in:

A-Z Index: